Compare AQMS & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AQMS | SNGX |
|---|---|---|
| Founded | 2014 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 8.2M |
| IPO Year | 2015 | 2006 |
| Metric | AQMS | SNGX |
|---|---|---|
| Price | $2.00 | $0.35 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 33.5K | ★ 208.9K |
| Earning Date | 11-11-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.03 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,100,000.00 | $119,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $600.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.96 | $0.28 |
| 52 Week High | $39.37 | $1.76 |
| Indicator | AQMS | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 33.51 | 34.93 |
| Support Level | N/A | $0.28 |
| Resistance Level | $2.98 | $0.41 |
| Average True Range (ATR) | 0.16 | 0.01 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 10.98 | 11.11 |
Aqua Metals Inc is developing and seeking to commercialize proprietary recycling and refining technologies for the recovery of critical minerals and metals. Its patented and patent-pending AquaRefining process is an electro-hydrometallurgical method designed to recover high-purity materials from battery and other metal-bearing feedstocks using a closed-loop system powered by electricity. Its idea is to reduce CAPEX and OPEX costs, reduce emissions, hazardous waste, and reliance on conventional smelting and chemical-intensive refining processes. It has one operating segment: sustainable metals recycling. It focused on the development and commercialization of AquaRefining technology for the clean and efficient recovery of valuable metals from lead-acid and lithium-ion batteries.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).